MA-INRUPT
23.7.2024 14:01:30 CEST | Business Wire | Press release
Today, Inrupt, the leading provider of enterprise-grade software for the web, announced the launch of its Data Wallet. Enterprises and governments use the technology to give their customers and citizens digital wallets for their data, creating a foundation for innovative, intuitive and impactful digital experiences.
Over 60% of the world’s population is expected to use digital wallets regularly by 2026, and over half of consumers report interest in using them for a broader range of purposes. But the existing market has focused largely on financial transactions and is dominated by a handful of Big Tech vendors.
Inrupt’s Data Wallet technology represents the next evolution of standard, interoperable digital wallets. Unlike alternatives, Inrupt’s solution accepts a wide variety of data and makes it easy for individuals to consent to access their data. The Data Wallet opens new opportunities for organizations as the web shifts toward a user-centric approach to how personal data is managed, shared, and used.
“Browsers shaped the Web 1.0 era, and Web 2.0 was all about apps. But Web 3.0 is all about empowered individuals and personal data. The Data Wallet becomes a fundamental tool for users,” said Sir Tim Berners-Lee, inventor of the World Wide Web and CTO and co-founder of Inrupt. “By making this key piece of technology available, Inrupt is ensuring that the opportunities and benefits of secure personal Data Wallets are open for everyone.”
The explosion of new use cases for digital wallets, and the types of data they store, represents a major shift in consumer behavior. For organizations, it’s a chance to improve and grow relationships with customers and citizens. In order to capitalize on the opportunity that digital wallets represent, organizations can rely on Inrupt’s standards-based approach to quickly build, integrate, and test new wallet offerings — or enhance their current wallet applications — all while giving users confidence that they have transparency and control of their most important personal data.
"Digital wallets are fast becoming the most compelling way to serve your customers and citizens. Organizations need to assess their wallet strategy,” said John Bruce, CEO and co-founder of Inrupt. “We built our Data Wallet to be easy to use — both for organizations and their users. It’s a direct channel of communication for valuable, relevant data."
Until now, digital wallets have been siloed “point solutions,” requiring different wallets for different purposes. But global initiatives like the EU’s Digital Identity Wallet are already showing organizations the benefits of standardization and interoperability. With a multi-purpose Data Wallet, organizations can access and verify government-issued credentials like passports, educational certificates and entitlement benefits, even across state and national borders.
Inrupt’s Data Wallet solution is built on the company’s Enterprise Solid Server (ESS), which is powering mission-critical deployments of the Solid protocol, the open web standard, around the world. Because of this foundation, it’s easy to reuse the personal data stored in the Data Wallet in other apps, services and AI systems. Consent for access is always coupled with each piece of data, so users can trust their data is used the way they want, and organizations can be confident they’re in compliance with any relevant data regulations.
“Digital wallets aren’t just for payments anymore. With the Data Wallet adding identity and consent capabilities, they are quickly becoming the gateway to our digital lives and will soon be the main interface used for data sharing, management and collaboration,” said Osmar Olivo, VP of Product at Inrupt. “By moving towards standardization with an underlying infrastructure like Solid, this wealth of information can be used flexibly, securely, and as intended across any sector in order to deliver better services, products, or experiences.”
“It’s clear that digital wallets are the new basecamp for a huge variety of digital activities. What’s not yet determined is whether this change will reinforce the power of the few, or open new advantages for the many,” said John Bruce. “Inrupt will always build technology intended to benefit the many, and our Data Wallet is the most important example yet.”
Click here to learn more about Inrupt’s Data Wallet features and capabilities or request a demo.
About Inrupt
Inrupt is a leading provider of enterprise-grade software for the web. Enterprises and governments rely on our technology to build new, innovative products and services — all based on a platform of interoperable data and consent from customers and citizens.
Co-founded by World Wide Web inventor Sir Tim Berners-Lee, Inrupt scales and secures the Solid protocol, the open web standard. The company’s Enterprise Solid Server (ESS) stores and protects personal data for enterprises and governments. On this foundation they can quickly build user Data Wallets and applications that take advantage of this new source of authentic data directly from customers and citizens.
Inrupt’s global presence spans the US, UK, Europe and APAC. The company works with organizations across various sectors, including Financial Services, Retail, Government, Healthcare, and Media/Telco. Founded in 2017, Inrupt’s mission is to ensure a better, safer future of data, AI, and the web.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723678725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
